

# THE LANCET

## Diabetes & Endocrinology

### **Supplementary appendix**

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Caussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. *Lancet Diabetes Endocrinol* 2020; published online May 18. [https://doi.org/10.1016/S2213-8587\(20\)30160-1](https://doi.org/10.1016/S2213-8587(20)30160-1).

## Supplementary material and methods

Supplementary methods .....	2
Study design and participants .....	2
Data collection and laboratory procedures .....	2
Definitions .....	3
Statistical analysis.....	3
Ethic committee approval .....	4
Supplementary results .....	5
Supplemental Figure 1: Study profiles .....	5
Supplemental Figure 2: Prevalence of obesity in COVID-19 inpatients aged <65 years compared with the French general population. ....	6
Supplemental Figure 3: Prevalence of obesity in COVID-19 inpatients in ICU compared to non-ICU in Lyon University Hospital.....	7
Supplemental Table 1: Baseline characteristics of patients with COVID-19 at Lyon University Hospital.....	8
Supplemental Table 2: Baseline characteristics of study groups in Lyon and Lille patient populations .....	9
Supplemental Table 3: Odds ratios of critical COVID-19 between patients with and without obesity in Lyon University Hospital, by risk factor adjustment .....	9
Supplemental Table 4: Univariate analyses of factors associated with COVID-19-ICU hospitalization in Lyon University Hospital.....	10
Role of the funding source .....	10
Data sharing .....	10
COVID-Outcomes-HCL Consortium .....	11
Lille COVID-Obesity Study group .....	11
References.....	13

## **Supplementary methods**

### **Study design and participants**

For this cross-sectional study of patients with COVID-19, we included a population of patients admitted for severe form of COVID-19 at Lyon University Hospital (Lyon, France). We also included a retrospective comparison group of patients admitted in intensive care unit (ICU) without COVID-19 from the same hospital. In addition, we performed additional analysis in a previously published population of ICU patients from Lille University Hospital, CHU Lille, Roger Salengro (Lille, France).<sup>1</sup>

The population included all adult ( $\geq 18$  years old) inpatients from Lyon University Hospital who were currently hospitalised on March 27, 2020, and had a confirmed diagnosis of COVID-19 according to WHO interim guidance.<sup>2</sup> Lyon University Hospital has set up specific COVID-19 departments to which all patients with a laboratory confirmed diagnosis by RT-PCR of COVID-19 or with as strong clinical and imaging suspicion of COVID-19 were transferred. All patients in this department were included except pregnant women.

For the ICU non-COVID-19 comparison group, we retrospectively included adult patients who had been admitted to ICU units for any indication in Lyon University Hospital on March 27<sup>th</sup> between 2007 and 2019. Patient data were obtained through a systematic extraction of a research institutional database registered according to the French reference methodology MR-004 number: 17-253. Because these patients were hospitalised before December, 2019, no COVID-19 cases could have been included in the comparison group.

We also performed additional analysis in a previously published population that comprised of adult patients diagnosed with COVID-19 pneumonia who were consecutively admitted to ICU at Roger Salengro Hospital, CHU Lille (Lille, France) between February 27 and April 5, 2020.<sup>1</sup> The independent comparison group comprised adult patients admitted to ICU at Lille University Hospital, CHU Lille, Roger Salengro for a non-SARS-CoV-2-related, severe acute respiratory disease from Jan 1, 2019, to Dec 31, 2019, extracted from electronic medical records in institutional database.<sup>1</sup>

### **Data collection and laboratory procedures**

We reviewed the electronic medical records including demographic, anthropometric data, medical history, medication and medical unit from all the departments exclusively dedicated to the clinical care of adult inpatients with COVID-19 hospitalised on March 27, 2020, at Lyon University Hospital.

SARS-CoV-2 infection was detected by real-time RT-PCR from respiratory specimens, bronchoalveolar lavage or nasopharyngeal samples. Briefly, 200  $\mu$ l of respiratory samples were inactivated in 400  $\mu$ l of cobas omni LYS buffer for 10 min before testing (Roche Diagnostics France). SARS-CoV-2 diagnosis was performed using the qualitative assay cobas SARS-CoV-2 kit on the cobas 6800 system as recommended by manufacturer's instructions (Roche diagnostics France). This technique targets the ORF1a nonstructural gene, specific for the SARS-CoV-2 detection and the structural envelope E-gene, detecting pan-Sarbecovirus including SARS-CoV-2. Amplification of RNA internal control is also included. The systematic extraction of positive RT-PCR for SARS-CoV-2 was matched with the identified patients in order to systematically exclude any patients admitted with a negative RT-PCR for SARS-CoV-2 despite a strong clinical suspicion of COVID-19.

All the clinical history was based upon extraction of the medical history from the electronic medical records. We have also collected medication information and have crossed the information between medical history and medication and the results were consistent.

As per standard procedure in Lyon University Hospital, all patients are weighted and measured in admission and data entered in the electronic medical record that we extracted for this study.

## **Definitions**

Confirmed COVID-19 was defined as a positive real-time RT-PCR for SARS-CoV-2 infection from respiratory specimens obtained by nasopharyngeal samples or bronchoalveolar lavage.

Obesity was defined by  $BMI \geq 30 \text{ kg/m}^2$ .

The severe forms of COVID-19 were defined by all inpatient for COVID-19 including ICU and non-ICU inpatients. The criteria for hospitalization due to severe form of COVID-19 were the requirement of oxygen therapy; patients older than 70 years with diarrhea or cognitive impairment or dehydration; renal impairment, severe lymphopenia.

The critical forms of COVID-19 were defined by the requiring ICU admission.

The criteria for ICU admission were based upon a standardised procedure implemented in the Lyon University Hospital since the beginning of COVID-19 pandemic. They included: oxygen therapy  $> 3\text{L}/\text{min}$  or saturation  $< 90\%$ , polypnea with respiratory rate  $> 25/\text{min}$ , signs of respiratory distress or vigilance disorders, hemodynamic instability, clammy skin, heart failure. These criteria were similar in Lille University Hospital.

## **Statistical analysis**

We present continuous variables as median (IQR) and categorical variables as n (%). Comparisons between groups were done using the independent Wilcoxon two-sample test,  $\chi^2$  test, or Fisher exact test, as appropriate.

The prevalence of obesity in patients with COVID-19 in both Lyon and Lille populations was compared with the prevalence in the French general population (considered as a reference population) using the Eurostat survey 2014<sup>3</sup>, standardised on age ( $\leq 65$  years *vs*  $> 65$  years) and sex (standardised prevalence ratio), using the indirect standardisation approach.<sup>4</sup> We have assumed that during the pandemic period of COVID-19, all individuals had the same risk of infection by COVID-19.

We used logistic regression to compare the prevalence of obesity between different groups within Lyon University Hospital population, adjusted by age ( $\leq 65$  years *vs*  $> 65$  years) and sex.<sup>4</sup> These analyses provided prevalence odds ratios (ORs) and 95% CIs. We compared the prevalence of obesity between ICU patients with and without COVID-19 in Lyon, adjusted for age ( $\leq 65$  years *vs*  $> 65$  years) and sex.<sup>4</sup> We also performed additional analysis in a previously published ICU population from Lille University Hospital<sup>1</sup> following the same statistical analysis by comparing the prevalence of obesity between the COVID-19 and non-COVID-19 ICU population using prevalence odds ratio adjusted for age and sex obtained by logistic regression.

Finally, we used logistic regression to do an exploratory analysis of the association between obesity and hospitalisation with critical COVID-19 (*vs* non-critical COVID-19) in the Lyon population, adjusted for age and sex. We performed univariable analyses of the association between specific and previously reported risk factors

of severity of COVID-19 and hospitalisation in ICU for critical COVID-19 (vs hospitalisation for non-critical COVID-19)<sup>5</sup> including presence of medical history of chronic pulmonary disease, immunodepression, malignancy, cardiomyopathy, dyslipidaemia, hypertension, or type 2 diabetes. We also performed multivariable analysis of the association between obesity and hospitalisation with critical COVID-19 (vs non-critical COVID-19) adjusted for these specific risk factors.

A two-sided  $\alpha$  of less than 0.05 was considered statistically significant. Statistical analyses were done using R (version 3.6.1).


### **Ethic committee approval**

The Hospices Civils de Lyon is the sponsor of this study. All the data collected from the identified patients were pseudonymized. In light of the situation of the health public emergency of the COVID-19 pandemic, a special dispensation regarding the principle of information and non-opposition of the patients related to their data processing have been granted. Thus, in accordance with the French regulation, this study has been considered to be consistent with the MR004 (Methodology of reference) and registered to the registry of the Hospices Civils de Lyon, handled by the Data Protection Officer.

The study was approved by the Research Ethics Commission of Lyon University Hospital (IRB number 20-44) and the requirement for written informed consent was waived by the Ethics Commission of the designated Hospital.


The observational study at Lille University Hospital was in strict compliance with the French reference methodology MR-004, established by French National Commission on Informatics and Liberties, and approved by the institutional data protection authority of CHU Lille.

## Supplementary results




### Supplemental Figure 1: Study profiles

(A) Population from Lyon University Hospital. (B) Population from Lille University Hospital<sup>1</sup>



**Supplemental Figure 2: Prevalence of obesity in COVID-19 inpatients aged <65 years compared with the French general population.**

The prevalence of obesity is presented stratified by age < 65 years and ≥ 65 years in the COVID-19 overall inpatient group from Lyon (light blue bar), patients in ICU from Lyon (dark blue bar), COVID-19 ICU inpatients from Lille (green bar) and in the French general population (white bar) according to Eurostat 2014 data<sup>3</sup>



**Supplemental Figure 3: Prevalence of obesity in COVID-19 inpatients in ICU compared to non-ICU in Lyon University Hospital.**

COVID-19 patients in intensive care unit (ICU) (blue bar, n=110), COVID-19 non-ICU group (orange bar, n=230).  
 POR: Prevalence Odds Ratio.



**Supplemental Table 1: Baseline characteristics of patients with COVID-19 at Lyon University Hospital**

	Overall (n=340)	BMI <30 kg/m <sup>2</sup> (n=255)	BMI ≥30 kg/m <sup>2</sup> (n=85)	p value*
<b>Demographics</b>				
Age ≥65 years	231 (68%)	192 (75%)	39 (46%)	<0.0001
Sex	..	..	..	0.568
Female	143 (42%)	110 (43%)	33 (39%)	..
Male	197 (58%)	145 (57%)	52 (61%)	..
<b>Clinical</b>				
Type 2 diabetes	72 (21%)	45 (18%)	27 (32%)	0.010
Hypertension	194 (57%)	144 (57%)	50 (59%)	0.857
Dyslipidaemia	88 (26%)	60 (24%)	28 (33%)	0.125
Cardiomyopathy	88 (26%)	73 (29%)	15 (18%)	0.058
Stroke	32 (9%)	24 (9%)	8 (9%)	1.000
Chronic pulmonary disease	65 (19%)	47 (19%)	18 (21%)	0.714
Malignancy	29 (9%)	25 (10%)	4 (5%)	0.218
Immunodepression	42 (12%)	38 (15%)	4 (5%)	0.021
Haemodialysis	3 (1%)	3 (1%)	0	0.576
<b>Hospitalisation units</b>				
Non-ICU ward (non-critical COVID-19)	230 (68%)	183 (72%)	47 (55%)	0.0074
ICU (critical COVID-19)	110 (32%)	72 (28%)	38 (45%)	0.0074

Data are n (%) or median (IQR), unless specified otherwise. ICU=intensive care unit. \*p value for the comparison between patients with BMI <30 kg/m<sup>2</sup> versus BMI ≥30 kg/m<sup>2</sup>, using independent Wilcoxon two-sample test,  $\chi^2$ , or Fisher exact test as appropriate.

**Supplemental Table 2: Baseline characteristics of study groups in Lyon and Lille patient populations**

	Lyon population					Lille population		
	Non-critical COVID-19 (n=230)	Critical COVID-19 (n=110)	ICU patients without COVID-19 (n=1210)	Non-critical vs critical COVID-19; p value	Critical COVID-19 vs ICU patients without COVID-19; p value	Critical COVID-19 (n=124)	ICU patients without COVID-19 (n=306)	Critical COVID-19 vs ICU patients without COVID-19; p value
Age ≥65 years	164 (71%)	67 (61%)	777 (64%)	0.072	0.014	47 (38%)	131 (43%)	0.408
Male sex	110 (48%)	87 (79%)	760 (63%)	<0.0001	0.00095	90 (73%)	107 (35%)	<0.0001
Obesity	47 (20%)	38 (35%)	314 (26%)	0.0074	0.066	59 (48%)	79 (26%)	<0.0001

Data are n (%). ICU=intensive care unit. p values determined using independent Wilcoxon two-sample test,  $\chi^2$  test, or Fisher exact test as appropriate. ICU=intensive care unit. Obesity is defined as BMI  $\geq 30$  kg/m<sup>2</sup>.

**Supplemental Table 3: Odds ratios of critical COVID-19 between patients with and without obesity in Lyon University Hospital, by risk factor adjustment**

	Odds ratio (95% CI) of ICU admission	p value*
Age, sex	2.16 (1.27–3.68)	0.0041
Hypertension, age, sex,	1.93 (1.10–3.39)	0.022
Dyslipidaemia, age, sex,	1.85 (1.05–3.26)	0.034
Type 2 diabetes, age, sex	1.80 (1.03–3.17)	0.040
Cardiomyopathy, age, sex	1.94 (1.11–3.40)	0.021
Chronic pulmonary disease, age, sex	2.03 (1.16–3.56)	0.013
Malignancy, age, sex	1.91 (1.09–3.34)	0.023
Immunodepression disease (including malignancy), age, sex	1.82 (1.03–3.20)	0.038

Odds ratios are calculated on all patients in Lyon University Hospital with severe COVID-19. ICU=intensive care unit. COVID-19=coronavirus disease 2019. \*p value determined using multivariable logistic regression.

**Supplemental Table 4: Univariate analyses of factors associated with COVID-19-ICU hospitalization in Lyon University Hospital**

Variable	OR of ICU hospitalization [95 % CI]	P-value
BMI $\geq$ 30 kg/m <sup>2</sup>	2.05 [1.24, 3.41]	0.006
Age < 65	1.59 [0.99, 2.57]	0.057
Male	4.15 [2.47, 7.20]	<0.001
Hypertension	1.21 [0.76, 1.93]	0.418
Dyslipidemia	1.92 [1.16, 3.17]	0.012
Type 2 Diabete	2.09 [1.22, 3.56]	0.007
No cardiomyopathy	1.73 [0.99, 3.02]	0.046
No chronic pulmonary disease	1.19 [0.66, 2.15]	0.560
No malignancy	2.45 [0.91, 6.60]	0.056
No immunodepression	4.01 [1.53, 10.50]	0.001

#### **Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication

#### **Data sharing**

Individual-participant data from Lyon University will be available upon request to the corresponding author. Data access will be provided to researchers after a proposal has been approved by an independent review committee identified for this purpose. The individual-participant data from Lille University are not publicly available, since they are subject to national data protection laws and restrictions imposed by the institutional data protection authority of CHU Lille to ensure data privacy of the study participants.

### **COVID-Outcomes-HCL Consortium**

Laurent Argaud, PhD (1), Frédéric Aubrun, PhD (2), Marc Bonnefoy, PhD (3), Maude Bouscambert-Duchamp, PhD (4), Roland Chapurlat, PhD (5), Dominique Chassard, PhD (6), Christian Chidiac, PhD (7), Michel Chuzeville, PhD (8), Cyrille Confavreux, PhD (9), Sébastien Couraud, PhD (10), Gilles Devouassoux, PhD (11), Isabelle Durieu, PhD (12), Michel Fessy, PhD (13), Sylvain Gaujard, PhD (14), Alexandre Gaymard, PhD (4), Arnaud Hot, PhD (15), Bruno Lina, PhD (4), Géraldine Martin Gaujard, PhD (16), Emmanuel Morelon, PhD (17), Vincent Piriou, PhD (18), Véronique Potinet, MD (19), Jean-Christophe Richard, PhD (20), Thomas Rimmele, PhD (21), Pascal Sève, PhD (22), Alain Sigal, PhD (23), Karim Tazarourte, PhD (24)

### **Lille COVID-Obesity Study group**

Enagnon Kazali Alidjinou, MD (25), Laurence Bocket, MD (25), Pauline Boddaert, MD (26), Robert Caiazzo, MD (27,28), Morgan Caplan, MD (26), Mikael Chetboun, MD (27,28), Nicolas Cousin, MD (26), Thibault Duburcq, MD (26), Alain Duhamel (29), Arthur Durand, MD (26), Ahmed El Kalioubie, MD (26), Raphael Favory, MD (26), Bruno Garcia, MD (26), Patrick Girardie, MD (26), Julien Goutay, MD (26), Marion Houard, MD (26), Emmanuelle Jaillette, MD (26), Nicolas Kostuj, MD (26), Julien Labreuch (29), Geoffrey Ledoux, MD (26), Anne Sophie Moreau, MD (26), Olivier Nigeon, MD (26), Christopher Niles, MD (26), Jérôme Noulette (27), Saad Nseir, MD (26), Thierry Onimus, MD (26), Erika Parmentier, MD (26), Julien Poissy, MD (26), Sebastien Préau, MD (26), Laurent Robriquet, MD (26), Anahita Rouze, MD (26), Arthur Simonnet, MD (26), Sophie Six, MD (26), Claire Tinez, MD (25), Aurélia Toussaint, MD (26), Violeta Raverdy, MD (27,28), Hélène Verkindt, MD (27,28),

### **Affiliations:**

- (1) Hospices Civils de Lyon, Département Médecine intensive et Réanimation, Hôpital Edouard Herriot, 69008 LYON, France
- (2) Hospices Civils de Lyon, Département Anesthésie et Réanimation, Hôpital de la Croix Rousse, 69004, Lyon, France
- (3) Hospices Civils de Lyon, Département Médecine du Vieillissement, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (4) Hospices Civils de Lyon, Département Virologie, Hôpital de la Croix Rousse, 69004, Lyon, France
- (5) Hospices Civils de Lyon, Département Rhumatologie et Pathologie osseuse, Hôpital Edouard Herriot, 69008 LYON, France
- (6) Hospices Civils de Lyon, Département Anesthésie et Réanimation, Hôpital Pierre Wertheimer, 69500 BRON, France
- (7) Hospices Civils de Lyon, Département Maladies infectieuses et tropicales, Hôpital de la Croix Rousse, 69004, Lyon, France
- (8) Hospices Civils de Lyon, Département Médecine du Vieillissement - Gériatrie, Hôpital Edouard Herriot, 69008 LYON, France
- (9) Hospices Civils de Lyon, Département Rhumatologie, Hôpital Lyon Sud, 69495 Pierre-Bénite, France

- (10) Hospices Civils de Lyon, Département Pneumologie, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (11) Hospices Civils de Lyon, Département Pneumologie, Hôpital de la Croix Rouse, 69004, Lyon, France
- (12) Hospices Civils de Lyon, Département Medecine Interne, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (13) Hospices Civils de Lyon, Département chirurgie orthopedique et traumatologique, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (14) Hospices Civils de Lyon, Département Médecine du Vieillissement, Hôpital de la Croix Rouse, 69004, Lyon, France
- (15) Hospices Civils de Lyon, Département Medecine Interne, Hôpital Edouard Herriot, 69008 LYON, France
- (16) Hospices Civils de Lyon, Département Médecine gériatrique, Hôpital Edouard Herriot, 69008 LYON, France
- (17) Hospices Civils de Lyon, Département Transplantation, Néphrologie et Immunologie Clinique , Hôpital Edouard Herriot, 69008 LYON, France
- (18) Hospices Civils de Lyon, Département Anesthésie et Réanimation, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (19) Hospices Civils de Lyon, Département Medecine d'Urgences, Hôpital Lyon Sud, 69495 Pierre-Bénite, France
- (20) Hospices Civils de Lyon, Département Medecine intensive et Réanimation, Hôpital de la Croix Rouse, 69004, Lyon, France
- (21) Hospices Civils de Lyon, Service d'anesthésie-réanimation, Hôpital Edouard Herriot, 69008 LYON, France
- (22) Hospices Civils de Lyon, Département Médecine Interne, Hôpital de la Croix Rouse, 69004, Lyon, France
- (23) Hospices Civils de Lyon, Département Medecine d'Urgence, Hôpital de la Croix Rouse, 69004, Lyon, France
- (24) Hospices Civils de Lyon, Département Urgences Médico-chirurgicales, Hôpital Edouard Herriot, 69008 LYON, France
- (25) CHU Lille, Laboratoire de Virologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, France
- (26) CHU Lille, Pôle de Réanimation, Hôpital Roger Salengro, F-59000, Lille, France
- (27) Inserm, Univ Lille, CHU Lille, Institut Pasteur Lille, European Genomic Institute for Diabetes, U1190, F-59000, Lille France
- (28) CHU Lille, Chirurgie Métabolique, Centre Intégré de l'Obésité, F-59000, Lille, France
- (29) CHU Lille, Univ Lille, ULR 2694 METRICS, F-59000, Lille, France

## References

- 1** Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)* 2020; published online April 9. DOI:10.1002/oby.22831.
- 2** Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, [press release]. 2020.
- 3** Eurostat database available from: <https://ec.europa.eu/eurostat>
- 4** Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. *Stat Med.* 2016;35(30):5730-5.
- 5** Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care.* 2020; 24: 108.